Cargando…
Adjunctive perampanel for glioma-associated epilepsy()
Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy. We conducted a single-arm study of adjunctive perampanel...
Autores principales: | Dunn-Pirio, Anastasie M., Woodring, Sarah, Lipp, Eric, Herndon, James E., Healy, Patrick, Weant, Mallika, Randazzo, Dina, Desjardins, Annick, Friedman, Henry S., Peters, Katherine B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202665/ https://www.ncbi.nlm.nih.gov/pubmed/30377587 http://dx.doi.org/10.1016/j.ebcr.2018.09.003 |
Ejemplares similares
-
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017) -
Efficacy of perampanel as an adjunctive therapy in pediatric focal epilepsy
por: Zhang, Wei-Ran, et al.
Publicado: (2023) -
A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab
por: Affronti, Mary Lou, et al.
Publicado: (2016) -
Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy
por: Youn, Song Ee, et al.
Publicado: (2018) -
Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)